Liedong Xu has been appointed executive vice president and chief operations officer at WuXiPRA. Mr. Xu has 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono.
 
Also, Jason Wu was appointed executive vice president and chief medical officer. He has 20 years of experience in clinical practice, clinical research, and product development, including management positions at Graceway, Auxillium, Sanofi, and Pfizer. 
 
WuXiPRA is a joint venture between WuXi PharmaTech and PRA established in 2012 to provide Phase I-IV clinical trial services in mainland China, Hong Kong and the Asia region. WuXiPRA is now the third largest clinical CRO in China and Hong Kong, with more than 400 employees. Its three business divisions focus on full-service clinical studies, strategic consulting, and global clinical informatics, respectively.
 
“We are very fortunate to have people of the caliber of Liedong and Jason leading our organization,” said Kent Thoelke, co-chief executive officer of WuXiPRA and executive vice president of PRA Health. “Their combined expertise will allow WuXiPRA to continue to build its successful operations throughout China.